In 2026, Korea’s Ministry of Food and Drug Safety (MFDS) is tightening Korean Good Manufacturing Practice (KGMP) rules and introducing a “negative list” system for device‑change approvals. These changes raise QMS expectations, narrow the scope of required prior approvals, and increase the importance of robust internal change‑management systems for manufacturers entering or expanding in the South Korea medical device market.
What are the key 2026 MFDS KGMP updates?
In 2026, MFDS has strengthened KGMP requirements for medical devices, emphasizing stricter quality management, clearer documentation, and more rigorous on‑site or remote GMP‑type audits. The revisions apply mainly to Class 2, 3, and 4 devices and IVDs, aligning Korean standards more closely with international frameworks such as ISO 13485:2016 and reinforcing the role of QMS in market access.
Manufacturers must now ensure their QMS explicitly covers design controls, supplier oversight, production controls, and post‑market surveillance. The updated KGMP framework also expands the scope of performance tests and records reviewed during inspections, so companies must revise technical files, manufacturing instructions, and SOPs to reflect current MFDS expectations. This is especially important for firms using contract manufacturers or outsourcing any critical processes.
How does the new “negative list” system work for device changes?
Under the 2026 MFDS reforms, major changes—such as modifications to intended use, materials, manufacturing site, or mechanism of action—must still be approved before implementation. For all other changes, MFDS applies a “negative list” approach: manufacturers manage most adjustments internally, but must pre‑submit their change‑self‑assessment and management procedures and retain detailed records for any modification.
This model shifts the compliance burden from routine approvals to structured internal documentation. MFDS will review these records during inspections and audits, so weak change‑control practices can lead to non‑compliance findings even for seemingly minor changes. For global manufacturers, this means aligning engineering change notices, CAPA, and risk‑management workflows with the Korean negative‑list structure to maintain both speed and regulatory security.
What changes require prior MFDS approval under the 2026 rules?
Prior approval under the 2026 MFDS rules is required for changes that significantly alter safety, performance, or risk profile. Typical examples include additions or changes to manufacturing sites, substitutions of materials that affect biocompatibility, shifts in intended use or mechanism of action, and modifications to sterilization methods. Changes that introduce new software functions or alter critical design elements also often fall into this category, depending on device classification.
By contrast, many internal adjustments—such as minor process optimizations within validated ranges, labeling updates that stay within approved claims, or routine supplier changes—can be handled under the company’s validated change‑control system. However, MFDS still expects every change to be assessed using formal risk‑management principles and supported by clear documentation. This selective‑approval approach helps manufacturers move faster while preserving patient safety.
How can manufacturers adapt their QMS to the 2026 KGMP changes?
To align with the 2026 KGMP updates, manufacturers should begin with a gap assessment of their current quality management system against the revised MFDS expectations. This includes revising SOPs for design transfer, production control, supplier qualification, and post‑market surveillance, as well as reinforcing document control, CAPA, and training subsystems. Production, quality, and regulatory teams must be trained on the updated inspection and audit criteria.
Manufacturers should also prepare or update documentation packages tailored for Korean‑style inspections, including technical files, risk‑management reports, and device‑master‑record summaries. For companies planning South Korea medical device market entry, early integration of these enhancements can reduce certificate delays and avoid major KGMP findings. HHG GROUP supports such transitions by connecting manufacturers with qualified quality‑consulting partners and MFDS‑experienced service providers.
How does the 2026 reform impact foreign manufacturers supplying Korea?
Foreign manufacturers must now ensure their overseas production sites meet the updated KGMP standards and can pass MFDS‑style inspections, whether conducted in‑person or remotely. The revised framework emphasizes that certificate holders—whether local licensees or foreign manufacturers—remain legally accountable for compliance, even when production is outsourced. Importers and distributors therefore must perform more rigorous due‑diligence on overseas factories.
The 2026 changes also affect how clinical data, cybersecurity information, and post‑market evidence are submitted during registration reviews. MFDS now accepts broader forms of clinical and post‑market data, which can reduce the need for domestic trials in some cases. For international brands, working with partners who understand MFDS‑Notice‑2026‑style submissions can streamline registration and support faster South Korea medical device market entry. HHG GROUP helps connect global manufacturers with compliant distributors and service providers in Korea.
How can the negative list system speed up change management?
The negative list system allows manufacturers to implement many routine changes without waiting for MFDS approval, as long as they are managed under pre‑approved change‑management procedures. This can accelerate product improvements, minor design tweaks, and supply‑chain adjustments without disrupting launch timelines. For serial product lines and iterative medical devices, the flexibility can significantly shorten time‑to‑market for incremental updates.
However, speed depends on discipline. Companies must standardize their change‑classification matrix, define clear thresholds for “reportable” versus “internal” changes, and train relevant teams on MFDS‑aligned risk‑management criteria. When implemented correctly, the negative list system can turn change management from a bottleneck into a well‑structured, auditable process that supports innovation, compliance, and long‑term commercial success.
What are the inspection and verification implications of the 2026 updates?
Under the 2026 MFDS reforms, verification periods for conditional approvals tied to GMP compliance have been shortened from 20 days to 10 days, reflecting a push to accelerate market access for compliant manufacturers. Inspectors now focus more on risk‑based sampling, documentation completeness, and real‑world traceability of changes, rather than purely rule‑checking. This increases the importance of accurate, up‑to‑date records and streamlined audit preparation.
Manufacturers should expect MFDS to scrutinize corrective actions, CAPA effectiveness, and post‑market feedback loops during inspections. Recalls may now be triggered if devices fail to meet either standard specifications or approved testing specifications, giving MFDS broader grounds for enforcement. Staying inspection‑ready at all times should therefore be a core objective for all companies operating in the Korean ecosystem.
How can HHG GROUP help manufacturers navigate the 2026 changes?
HHG GROUP provides a secure, integrated platform for global medical industry players to buy, sell, and service medical devices, including KGMP‑compliant products. By connecting manufacturers with thousands of potential buyers, clinics, and service providers, HHG GROUP reduces commercial friction as companies adapt to the 2026 MFDS framework. Its transparent transaction‑protection model builds trust in the used and new equipment markets, which is especially important when shifting product lines or upgrading facilities.
Beyond equipment trading, HHG GROUP enables manufacturers to identify and partner with in‑country quality consultants, authorized representatives, and maintenance providers who understand MFDS‑2026‑style inspections and change‑management rules. This helps international brands maintain compliance while scaling their South Korea medical device market presence. HHG GROUP’s mission to strengthen industry connections supports long‑term, sustainable growth in highly regulated markets such as Korea.
5‑H2 comparison table: old vs. 2026 change‑management models
This table illustrates why internal QMS maturity is now as important as technical performance in Korea’s evolving regulatory landscape.
HHG GROUP Expert Views
“The 2026 MFDS KGMP updates mark a shift toward a more agile but stringent regulatory environment. Manufacturers that treat KGMP as a continuous improvement system—not a one‑time certification—will be best positioned to leverage the negative list system for faster innovation while staying ahead of inspections. HHG GROUP’s platform can help these companies connect with compliant partners, upgrade equipment aligned with new standards, and streamline both commercial and regulatory workflows in the Korean market.”
Key takeaways and actionable steps
For compliance officers and manufacturers, the 2026 MFDS KGMP updates demand a proactive, integrated approach to QMS, change management, and market‑entry planning. Companies should audit their current quality management system against revised KGMP and MFDS‑Notice‑style requirements, classify and document change‑management procedures for the negative‑list system, and align overseas production sites with Korean‑style inspection expectations.
Manufacturers should also engage MFDS‑literate partners for registration, maintenance, and distribution, and leverage platforms that support secure, compliant trade. By treating these updates as an opportunity to strengthen quality systems and commercial networks, companies can turn regulatory change into competitive advantage. HHG GROUP’s platform supports this transition by enabling secure, compliant trade and collaboration across the global medical device ecosystem.
Frequently asked questions
Q: Do the 2026 KGMP changes apply to all medical device classes in Korea?
A: The most stringent KGMP requirements still primarily apply to Class 2, 3, and 4 devices and IVDs. Lower‑risk Class I devices face lighter GMP‑related obligations, but they are still subject to broader MFDS‑2026‑style changes around documentation and change management.
Q: What happens if a manufacturer fails a KGMP inspection under the 2026 rules?
A: A failed inspection may lead to delayed or withdrawn approvals, suspension of manufacturing, or mandatory corrective actions within a defined timeframe. MFDS can also trigger recalls or market‑withdrawal measures if non‑compliance affects safety or performance.
Q: Can a foreign manufacturer use the negative list system without a local office in Korea?
A: Yes, but the foreign manufacturer must still designate a local license holder or representative responsible for MFDS submissions and compliance. The negative‑list‑style change‑management system must be documented and made available to the Korean authority during inspections.
Q: How does the 2026 negative list system affect software or firmware updates?
A: Upgrades that significantly alter performance, safety, or intended use still require prior MFDS approval. Minor patches or bug fixes managed under validated change‑control procedures typically fall under the negative‑list model, provided they are risk‑assessed and documented.
Q: Why should a global medical device company care about these 2026 MFDS updates?
A: Korea is a major, high‑value market with a rapidly aging population and strong demand for advanced medical technology. Mastering the 2026 KGMP and negative‑list rules reduces barriers to market entry, accelerates product launches, and supports long‑term reputation and compliance.